Chronic immune response dysregulation in MDS pathogenesis-Reference-Cited by-同舟云学术

Chronic immune response dysregulation in MDS pathogenesis

Published:2018-10-11 Issue:15 Volume:132 Page:1553-1560
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Barreyro Laura¹^ORCID,Chlon Timothy M.¹²,Starczynowski Daniel T.¹²

Affiliation:

1. Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; and

2. Department of Cancer Biology, University of Cincinnati, Cincinnati, OH

Abstract

Abstract Chronic innate immune signaling in hematopoietic cells is widely described in myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly via pattern recognition receptors, increases the risk of developing MDS. An inflammatory component to MDS has been reported for many years, but only recently has evidence supported a more direct role of chronic innate immune signaling and associated inflammatory pathways in the pathogenesis of MDS. Here we review recent findings and discuss relevant questions related to chronic immune response dysregulation in MDS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/15/1553/1406922/blood784116.pdf

Reference112 articles.

1. Chronic exposure to a TLR ligand injures hematopoietic stem cells;Esplin;J Immunol,2011

2. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow;Hofmann;Blood,2002

3. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells;Pellagatti;Leukemia,2010

4. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes;Maratheftis;Clin Cancer Res,2007

5. Toll-like receptor alterations in myelodysplastic syndrome;Wei;Leukemia,2013

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer;Acta Pharmaceutica Sinica B;2024-09

2. New insights into PSAT1 as a therapeutic target for myelodysplastic syndrome (MDS);PLOS ONE;2024-08-26

3. The immunoregulatory role of monocytes and thrombomodulin in myelodysplastic neoplasms;Frontiers in Oncology;2024-07-26

4. DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy;Leukemia;2024-06-27

5. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation;Stem Cell Reviews and Reports;2024-06-17